SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.

"Duality of Interest. J.Z. has received research funding from various pharmaceutical companies to support the application of MR to drug target prioritization. No other potential conflicts of interest relevant to this article were reported."

"Funding. This work was funded by the National Natural Science Foundation of China (81941017, 81930021, 81970728, 81970706, 82022011, 82270859, 91857205, and 82088102), the Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant Support (20152508 Round 2), and the Shanghai Shenkang Hospital Development Center (SHDC12019101, SHDC2020CR1001A, and SHDC2020CR3064B). M.X., T.W., J.L., M.L., Y.X., G.N., Y.B., and W.W. are members of the Innovative Research Team of High-level Local Universities in Shanghai. J.Z. is supported by the Academy of Medical Sciences Springboard Award, the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation, and Diabetes UK (SBF006\1117). J.Z. is funded by the Vice-Chancellor Fellowship from the University of Bristol. J.Z. is supported by Shanghai Thousand Talents Program."